The FASEB Journal, Vol 4, 3068-3075, Copyright © 1990 by The Federation of American Societies for Experimental Biology

REVIEWS

Heart failure: mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention

GS Francis and JN Cohn
Department of Medicine, University of Minnesota Medical School, Minneapolis 55455.

Congestive heart failure is a complex clinical syndrome that has its basis in an abnormality of myocardial cell function resulting in impaired ventricular performance, exercise intolerance, and ventricular arrhythmias. The functional defect in myocardial performance may be related to alterations in receptor function, in regulatory proteins, or in biochemical mechanisms. Remodeling of the left ventricle has been observed to play an important role in the natural course of heart failure. The complex interplay between cellular elongation, reactive hypertrophy, and the influence of the change from ellipsoid to spheroidal shape of the left ventricle after acute myocardial infarction are just beginning to be understood. Prevention of this remodeling effect by pharmacologic intervention is being widely explored, although the mechanisms are poorly defined. Impedance to left ventricular ejection is also an important determinant of cardiac performance in heart failure. Constriction of arteriolar resistance vessels and reduction in compliance of arterial conductance vessels is a common manifestation of heart failure and may be under the influence of neural, hormonal, endothelial, and local regulatory factors. Increased tone of venous capacitance vessels contributes to a shift of blood centrally and to an increase in ventricular preload. Vasodilator drugs by relaxing the arterial, arteriolar, and venous vasculature result in a reduction in impedance and left ventricular afterload and a decrease in cardiac filling pressure and preload. Structural changes of hypertrophy and remodeling apparently contribute to the changes in resistance, compliance, and capacitance in the vasculature. Treatment of heart failure is aimed at relieving symptoms and prolonging life. Interventions to improve left ventricular function are critical to symptom relief. Vasodilators have been most effective for this purpose, and new positive inotropic drugs are being tested for efficacy. Long- term benefit may require interference with the myocardial and peripheral vascular remodeling processes that lead to progressive depression of ventricular performance. New insights into the cellular and subcellular mechanisms of this progression are critical to the development of innovative therapeutic strategies.

This article has been cited by other articles:

				S Kasama, T Toyama, T Hatori, H Sumino, H Kumakura, Y Takayama, S Ichikawa, T Suzuki, and M Kurabayashi Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure Heart, October 1, 2006; 92(10): 1434 - 1440. [Abstract] [Full Text] [PDF]

				S Kasama, T Toyama, T Hatori, H Sumino, H Kumakura, Y Takayama, S Ichikawa, T Suzuki, and M Kurabayashi Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure Heart, May 1, 2006; 92(5): 625 - 630. [Abstract] [Full Text] [PDF]

				S. M. Karim, A. Y. Rhee, A. M. Given, M. D. Faulx, B. D. Hoit, and F. V. Brozovich Vascular Reactivity in Heart Failure: Role of Myosin Light Chain Phosphatase Circ. Res., September 17, 2004; 95(6): 612 - 618. [Abstract] [Full Text] [PDF]

				S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, T. Ishikawa, S. Ichikawa, T. Suzuki, and M. Kurabayashi Effects of Intravenous Atrial Natriuretic Peptide on Cardiac Sympathetic Nerve Activity in Patients with Decompensated Congestive Heart Failure J. Nucl. Med., July 1, 2004; 45(7): 1108 - 1113. [Abstract] [Full Text] [PDF]

				J. N. Cohn Clinical Research: Whose Agenda Is It? Circulation, May 18, 2004; 109(19): 2256 - 2262. [Full Text] [PDF]

				R. C. Arora, R. Cardinal, F. M. Smith, J. L. Ardell, L. J. Dell'Italia, and J. A. Armour Intrinsic cardiac nervous system in tachycardia induced heart failure Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2003; 285(5): R1212 - R1223. [Abstract] [Full Text] [PDF]

				S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi Addition of Valsartan to an Angiotensin-Converting Enzyme Inhibitor Improves Cardiac Sympathetic Nerve Activity and Left Ventricular Function in Patients with Congestive Heart Failure J. Nucl. Med., June 1, 2003; 44(6): 884 - 890. [Abstract] [Full Text] [PDF]

				J. N. Cohn, G. Tognoni, and the Valsartan Heart Failure Trial Investigators A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure N. Engl. J. Med., December 6, 2001; 345(23): 1667 - 1675. [Abstract] [Full Text] [PDF]

				E. Omerovic, E. Bollano, R. Mobini, V. Kujacic, B. Madhu, B. Soussi, M. Fu, A. Hjalmarson, F. Waagstein, and J. Isgaard Growth Hormone Improves Bioenergetics and Decreases Catecholamines in Postinfarct Rat Hearts Endocrinology, December 1, 2000; 141(12): 4592 - 4599. [Abstract] [Full Text] [PDF]

				K. Eizema, H. Fechner, K. Bezstarosti, S. Schneider-Rasp, A. van der Laarse, H. Wang, H.-P. Schultheiss, W. C. Poller, and J. M. J. Lamers Adenovirus-Based Phospholamban Antisense Expression as a Novel Approach to Improve Cardiac Contractile Dysfunction : Comparison of a Constitutive Viral Versus an Endothelin-1-Responsive Cardiac Promoter Circulation, May 9, 2000; 101(18): 2193 - 2199. [Abstract] [Full Text] [PDF]

				P. P de Tombe Altered contractile function in heart failure Cardiovasc Res, February 1, 1998; 37(2): 367 - 380. [Abstract] [Full Text] [PDF]

				J. N. Cohn Is There a Role for Endothelin in the Natural History of Heart Failure? Circulation, August 15, 1996; 94(4): 604 - 606. [Full Text]

				K. Kimura, B. H. White, and A. Sidhu Coupling of Human D-1 Dopamine Receptors to Different Guanine Nucleotide Binding Proteins J. Biol. Chem., June 16, 1995; 270(24): 14672 - 14678. [Abstract] [Full Text] [PDF]